{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00167",
      "entity_text" : "FGF",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11451527",
      "entity_text" : "brivanib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "All Phase III studies with sunitinib (angiogenesis inhibitor), XREF_BIBR linifanib (angiogenesis kinase inhibitor), XREF_BIBR and brivanib (inhibitor of VEGF and FGF receptors) XREF_BIBR failed in demonstrating superiority of these agents over sorafenib.",
  "reading_complete" : "2020-08-05T22:30:27Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:29:13Z",
  "trigger" : "inhibitor",
  "evidence" : [ "brivanib (inhibitor of VEGF and FGF" ],
  "pmc_id" : "4109634",
  "score" : 0
}